International Agency for Research on Cancer, Lyon, France.
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.
J Thorac Oncol. 2022 Feb;17(2):252-263. doi: 10.1016/j.jtho.2021.10.001. Epub 2021 Oct 11.
We propose a risk-tailored approach for management of lung cancer screening results. This approach incorporates individual risk factors and low-dose computed tomography (LDCT) image features into calculations of immediate and next-screen (1-y) risks of lung cancer detection, which in turn can recommend short-interval imaging or 1-year or 2-year screening intervals.
We first extended the "LCRAT+CT" individualized risk calculator to predict lung cancer risk after either a negative or abnormal LDCT screen result. To develop the abnormal screen portion, we analyzed 18,129 abnormal LDCT results in the National Lung Screening Trial (NLST), including lung cancers detected immediately (n = 649) or at the next screen (n = 235). We estimated the potential impact of this approach among NLST participants with any screen result (negative or abnormal).
Applying the draft National Health Service (NHS) England protocol for lung screening to NLST participants referred 76% of participants to a 2-year interval, but delayed diagnosis for 40% of detectable cancers. The Lung Cancer Risk Assessment Tool+Computed Tomography (LCRAT+CT) risk model, with a threshold of less than 0.95% cumulative lung cancer risk, would also refer 76% of participants to a 2-year interval, but would delay diagnosis for only 30% of cancers, a 25% reduction versus the NHS protocol. Alternatively, LCRAT+CT, with a threshold of less than 1.7% cumulative lung cancer risk, would also delay diagnosis for 40% of cancers, but would refer 85% of participants for a 2-year interval, a 38% further reduction in the number of required 1-year screens beyond the NHS protocol.
Using individualized risk models to determine management in lung cancer screening could substantially reduce the number of screens or increase early detection.
我们提出了一种针对肺癌筛查结果的风险定制管理方法。该方法将个体风险因素和低剂量计算机断层扫描(LDCT)图像特征纳入到肺癌检测的即时和下一次筛查(1 年)风险的计算中,从而可以推荐短间隔成像或 1 年或 2 年筛查间隔。
我们首先扩展了“LCRAT+CT”个体化风险计算器,以预测阴性或异常 LDCT 筛查结果后的肺癌风险。为了开发异常筛查部分,我们分析了国家肺癌筛查试验(NLST)中的 18129 例异常 LDCT 结果,包括立即(n=649)或下一次筛查(n=235)检测到的肺癌。我们估计了该方法在任何筛查结果(阴性或异常)的 NLST 参与者中的潜在影响。
根据英国国民保健署(NHS)英格兰肺癌筛查协议,对 NLST 参与者进行应用,将 76%的参与者推荐至 2 年间隔,但会使 40%的可检测癌症延迟诊断。肺癌风险评估工具+计算机断层扫描(LCRAT+CT)风险模型,其累积肺癌风险阈值小于 0.95%,也将有 76%的参与者被推荐至 2 年间隔,但仅会延迟 30%的癌症诊断,与 NHS 协议相比,减少了 25%。或者,LCRAT+CT,其累积肺癌风险阈值小于 1.7%,也将使 40%的癌症延迟诊断,但会将 85%的参与者推荐至 2 年间隔,与 NHS 协议相比,进一步减少了 1 年筛查所需的人数的 38%。
使用个体化风险模型来确定肺癌筛查的管理方法可以显著减少筛查次数或提高早期检测率。